Availability of quality fixed-dose combinations for the treatment of tuberculosis: What can we learn from studying the World Health Organization's vaccine model?

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 11 SUPPL. 3, 1999, Pages

  Blomberg, B ^b   Kitler, M E ^c   Milstien, J ^a   Dellepiane, N ^a   Fanning, A ^c   Norval, P Y ^c   Spinaci, S ^c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Dept for Endemic Diseases Control   (Switzerland)

^c NONE

Author keywords

Drug combinations; Drug therapy; Quality control tuberculosis; Vaccines

Indexed keywords

BCG VACCINE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE;

BCG VACCINATION; CONFERENCE PAPER; DRUG FORMULATION; DRUG MANUFACTURE; DRUG QUALITY; HUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG AND NARCOTIC CONTROL; DRUG COMBINATIONS; DRUG INDUSTRY; HUMANS; QUALITY CONTROL; TUBERCULOSIS; VACCINES; WORLD HEALTH ORGANIZATION;

EID: 0032711267     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Moulding T, Dutt A K, Reichman L B. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 1995; 122: 951-954.
2. Maher D, Chaulet P, Spinaci S, Harries A D. Treatment of tuberculosis. Guidelines for National Programmes. WHO Document WHO/TB/97/220. Geneva: WHO, 1997.
3. Sbarbaro J A. Reality versus the academic milieu [Editorial]. Am Rev Respir Dis 1986; 134: 1109.
4. Sbarbaro J A. A challenge - to our practices and to our principles [Editorial; comment]. Tubercle Lung Dis 1996; 77: 2-3.
5. International Federation of Pharmaceutical Manufacturers Association (IFPMA). Symposium on combination products for the treatment of tuberculosis, 6-7 December 1994, Geneva Switzerland. Report. Geneva: International Federation of Pharmaceutical Manufacturers Association (IFPMA), 1994.
6. The promise and the reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Diseases and the Tuberculosis Programme of the World Health Organization. Tubercle Lung Dis 1994; 75: 180-181.
7. Acocella G. Human bioavailability studies (IUATLD Symposium "Quality control of antituberculosis drugs", Dubrovnik, 6 October 1988). Bull Int Union Tuberc Lung Dis 1989; 64: 38-40.
8. Acocella G, Conti R, Luisetti M, Pozzi E, Grassi C. Pharmacokinetic studies on antituberculosis regimens in humans. I. Absorption and metabolism of the compounds used in the initial intensive phase of the short-course regimens: single administration study. Am Rev Respir Dis 1985; 132: 510-515.
9. Acocella G, Nonis A, Perna G, Patane E, Gialdroni-Grassi G, Grassi C. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study. Am Rev Respir Dis 1988; 138: 886-890.
10. Acocella G, Nonis A, Gialdroni-Grassi G, Grassi C. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study. Am Rev Respir Dis 1988; 138: 882-885.
11. Acocella G, Luisetti M, Grassi G G, Peona V, Pozzi E, Grassi C. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy. Monaldi Arch Chest Dis 1993; 48: 205-209.
12. Ellard G A, Ellard D R, Allen B W, et al. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. Am Rev Respir Dis 1986; 133: 1076-1080.
13. Fox W. Drug combinations and the bioavailability of rifampicin. Tubercle 1990; 71: 241-245.
14. Schall R, Muller F O, Duursema L, et al. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol. Arzneimittelforschung 1995; 45: 1236-1239.
15. World Health Organization. Essential Drugs, WHO model list (revised in December 1997). WHO Drug Information 1998; 12: 22-25.
16. Norval P-Y, Blomberg B, Kitler M E, Dye C, Spinaci S. Estimate of the global market for rifampicin-containing fixed-dose combination tablets. Int J Tuberc Lung Dis 1999; 3 (Suppl): S292-S300.
17. World Health Organization. Report and recommendations from the meeting of the Technical Research and Advisory Committee (TRAC), 17-19 August 1998, Geneva. Geneva: WHO, 1998.
18. Milstien J B, Gibson J J. Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ 1990; 68: 93-108.
19. Davey S. World Health Organization. Global Programme for Vaccine and Immunization 1998. WHO/GPV/98.03. Geneva: WHO, 1998.
20. World Health Organization. A network to 'eradicate' poor-quality vaccines. Vaccine and Immunization News, the newsletter ot the Global Programme for Vaccines and Immunization. No 6, March 1998. GPV/VIN/98.01. Geneva: WHO, 1998.
21. Melgaard B. Immunization and health reform: The implications of decentralisation. GPV-CVI/SAGE.98/WP.13. Geneva: World Health Organization, 1998.
22. Evans P. Procurement of vaccines: Roles and responsibility. GPV-CVI/SAGE.98/WP.09. Geneva: WHO, 1998.
23. Children's Vaccine Initiative/World Health Organization. Vaccine self-sufficiency: improving local production and quality control. CVI/94.2. Geneva: WHO, 1994.
24. World Health Organization. Vaccine quality. A quality programme needs quality vaccines. EPI UPDATE No. 28, 1995-995/10648. Geneva: WHO, 1995.
25. World Health Organization. Ensuring the quality of locally produced vaccines and the viability of local production, GPV Policy Statement. WHO/VSQ/98.03. Geneva: WHO, 1998.
26. World Health Organization. Guidelines for the international procurement of vaccines and sera. WHO/VSQ/98.05. Geneva: WHO, 1998.
27. World Health Organization. National Control Authority. Guidelines for assessment of vaccine quality in non-producing countries. WHO/VSQ/95.1. Geneva: WHO, 1995.
28. Bruning J H, van Nimwegen F, van der Gun J W, di Fabio J L. Manual of laboratory methods for testing of vaccines used in the WHO Expanded Programme on Immunization. WHO/ VSQ/97.04. Geneva: WHO, 1997.
29. Milstien J, Villar T. The Global Training Network: Ensuring good quality vaccine throughout the world. WHO/VSQ/97.07. Geneva: WHO, 1998.
30. World Health Organization. Third annual meeting of the Advisory Committee on Training (ACT). WHO/VSQ/98.01. Geneva: WHO, 1998.
31. World Health Organization. The Vaccine Supply and Quality Unit. Assuring an adequate and sustainable supply of affordable, high quality vaccine for the implementation of present and future disease control strategies of national immunisation programmes. WHO/VSQ/98.02. Geneva: WHO, 1998.
32. World Health Organization. Demand forecasting: What are the models we can use to forecast aggregate demand for vaccine manufacturing? GPV-CVI/SAGE.98/WP.11. Geneva: WHO, 1998.
33. Milstien J, Batson A, Meaney W. A systematic method for evaluating the potential viability of local vaccine producers. Vaccine 1997; 15: 1358-1363.
34. Batson A, Evans P, Milstien J B. The crisis in vaccine supply: a framework for action. Vaccine 1994; 12: 963-965.
35. World Health Organization. Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies. WHO/VSQ/97.06. Geneva: WHO, 1997.
36. Milstien J B, Gellin B G, Kane M, di Fabio J L, Homma A. Global DTP manufacturing capacity and capability. Status report: January 1995. Vaccine 1996; 14: 313-320.
37. World Health Organization. Report of the meeting of the Scientific Advisory Group of Experts (SAGE), Geneva, 9-11 June 1998. Children Vaccine Initiative, Global Programme for Vaccines and Immunization. WHO/GPV/98.06. Geneva: WHO, 1998.
38. Maher D, Mikulencak M. What is DOTS? A guide to understanding the WHO-recommended TB control strategy known as DOTS. WHO/CDS/CPC/TB/99.270. Geneva: WHO, 1999.
39. Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers. Int J Tuberc Lung Dis 1999; 3 (Suppl): S284-S285.
40. Laing R, Fourie B, Ellard G, et al. World Health Organization. Fixed dose combination tablets for the treatment of tuberculosis. Report from an informal meeting held in Geneva, Tuesday, 27 April 1999. WHO/CDS/CPC/TB/99.267. Geneva: WHO, 1999.
41. Chaulet P, Boulahbal F. Essai clinique d'une combinaison en proportions fixes de trois medicaments dans le traitement de la tuberculose [Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis.] Groupe de Travail sur la Chimiotherapic de la Tuberculose. Tubercle Lung Dis 1995; 76: 407-412.
42. Hong Kong Chest Service/British Medical Research Council. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy. Am Rev Respir Dis 1989; 140: 1618-1622.
43. Snider D E, Graczyk J, Bek E, Rogowski J. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin. Am Rev Respir Dis 1984; 110: 1091-1094.
44. East African and British Medical Research Councils. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report of 4th study. Lancet 1978; 2: 334-338.
45. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119: 579-85.
46. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. Br J Dis Chest 1981; 75: 141-153.
47. Kitler M E. The fixed dose combination project. An evaluation of the current status of the project and recommendations for strategic planning for future action. National Programme Support. The Global Tuberculosis Programme. Geneva: WHO, 1998. Unpublished document.
48. Management Sciences for Health. International Drug Price Indicator Guide (1991-1996). Arlington, VA, Washington, DC: Management Sciences for Health, The World Bank, 1991-1996.
49. Mahmoudi A, Iseman M D. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA 1993; 270: 65-68.